风湿免疫指南

订阅

MedSci主页 / 所有栏目 / 风湿免疫指南

2022 中国台湾共识建议：类风湿关节中选定共病，包括心血管病、骨质疏松和间质性肺病的管理

2022-01-07 中国风湿免疫科相关专家小组（统称） Medicine (Baltimore)

类风湿关节炎骨质疏松症间质性肺病心血管病共病

类风湿关节炎（RA）相关共病，包括心血管病、骨质疏松和间质性肺可影响疾病控制并导致生活质量受损。本文主要针对类风湿关节中选定共病，包括心血管病、骨质疏松和间质性肺病的管理提供共识建议。

中文标题：

2022 中国台湾共识建议：类风湿关节中选定共病，包括心血管病、骨质疏松和间质性肺病的管理

发布机构：

中国风湿免疫科相关专家小组（统称）

发布日期：

2022-01-07

简要介绍：

类风湿关节炎（RA）相关共病，包括心血管病、骨质疏松和间质性肺可影响疾病控制并导致生活质量受损。本文主要针对类风湿关节中选定共病，包括心血管病、骨质疏松和间质性肺病的管理提供共识建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 中国台湾共识建议：类风湿关节中选定共病，包括心血管病、骨质疏松和间质性肺病的管理 (1).pdf)] GetToolGuiderByIdResponse(projectId=1, id=0e79f1c00232352f, title=2022 中国台湾共识建议：类风湿关节中选定共病，包括心血管病、骨质疏松和间质性肺病的管理, enTitle=, guiderFrom=Medicine (Baltimore), authorId=0, author=, summary=类风湿关节炎（RA）相关共病，包括心血管病、骨质疏松和间质性肺可影响疾病控制并导致生活质量受损。本文主要针对类风湿关节中选定共病，包括心血管病、骨质疏松和间质性肺病的管理提供共识建议。, cover=, journalId=0, articlesId=null, associationId=881, associationName=中国风湿免疫科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Fri Jan 07 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">类风湿关节炎（RA）相关共病，包括心血管病、骨质疏松和间质性肺可影响疾病控制并导致生活质量受损。本文主要针对类风湿关节中选定共病，包括心血管病、骨质疏松和间质性肺病的管理提供共识建议。</span></p>, tagList=[TagDto(tagId=457, tagName=类风湿关节炎), TagDto(tagId=644, tagName=骨质疏松症), TagDto(tagId=1845, tagName=间质性肺病), TagDto(tagId=1849, tagName=心血管病), TagDto(tagId=1888, tagName=共病)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21023, categoryName=赛诺菲-赛能, tenant=100), CategoryDto(categoryId=21067, categoryName=梅斯医学-骨质疏松网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5474, appHits=150, showAppHits=0, pcHits=623, showPcHits=5324, likes=0, shares=24, comments=4, approvalStatus=1, publishedTime=Mon Jan 17 19:25:17 CST 2022, publishedTimeString=2022-01-07, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Mon Jan 17 19:28:48 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 10:47:45 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 中国台湾共识建议：类风湿关节中选定共病，包括心血管病、骨质疏松和间质性肺病的管理 (1).pdf)])
2022 中国台湾共识建议：类风湿关节中选定共病，包括心血管病、骨质疏松和间质性肺病的管理 (1).pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1188676, encodeId=ff8911886e6a0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42102618663, createdName=renwei2011, createdTime=Thu Jan 27 21:10:56 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185477, encodeId=343c11854e7f4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 18 07:24:13 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185322, encodeId=18f8118532258, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Mon Jan 17 20:55:36 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-01-27 renwei2011

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1188676, encodeId=ff8911886e6a0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42102618663, createdName=renwei2011, createdTime=Thu Jan 27 21:10:56 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185477, encodeId=343c11854e7f4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 18 07:24:13 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185322, encodeId=18f8118532258, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Mon Jan 17 20:55:36 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-01-18 微探

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1188676, encodeId=ff8911886e6a0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42102618663, createdName=renwei2011, createdTime=Thu Jan 27 21:10:56 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185477, encodeId=343c11854e7f4, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Jan 18 07:24:13 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185322, encodeId=18f8118532258, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f94874946, createdName=tyiutyu16, createdTime=Mon Jan 17 20:55:36 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-01-17 tyiutyu16

    学习了

    0

相关指南

2021 KNGF临床实践指南：类风湿性关节炎患者的物理治疗管理

荷兰皇家物理治疗学会(KNGF,Royal Dutch Society for Physical Therapy) · 2021-08-01

2021 药师共识指南：类风湿关节炎患者生物制剂过渡的监测

国外药师专家小组（统称） · 2021-09-14

类风湿关节炎相关自身抗体检测的临床应用专家共识

中国医师协会风湿免疫科医师分会 · 2021-06-17

2021 ACR指南：类风湿关节炎的治疗

美国风湿病学会(ACR,American College of Rheumatology) · 2021-06-08

类风湿关节炎中西医结合医疗质量控制指标专家共识（2021年版）

暂未更新 · 2021-02-20

雷公藤多苷/雷公藤片治疗类风湿关节炎的临床实践指南 2021

暂未更新 · 2021-01-14